MX2020009757A - Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades. - Google Patents

Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades.

Info

Publication number
MX2020009757A
MX2020009757A MX2020009757A MX2020009757A MX2020009757A MX 2020009757 A MX2020009757 A MX 2020009757A MX 2020009757 A MX2020009757 A MX 2020009757A MX 2020009757 A MX2020009757 A MX 2020009757A MX 2020009757 A MX2020009757 A MX 2020009757A
Authority
MX
Mexico
Prior art keywords
inhibitor
bcl
prevention
treatment
combination product
Prior art date
Application number
MX2020009757A
Other languages
English (en)
Inventor
Dajun Yang
Yifan Zhai
Qiuqiong Tang
Douglas Dong Fang
Original Assignee
Ascentage Pharma Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascentage Pharma Suzhou Co Ltd filed Critical Ascentage Pharma Suzhou Co Ltd
Publication of MX2020009757A publication Critical patent/MX2020009757A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

En la presente se proporciona un producto combinado que comprende un inhibidor de Bcl-2 y un inhibidor de MDM-2, proporcionando el producto combinado un uso en la prevención y/o tratamiento de enfermedades (por ejemplo, cáncer).
MX2020009757A 2018-07-31 2019-07-22 Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades. MX2020009757A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810862170 2018-07-31
PCT/CN2019/096968 WO2020024820A1 (en) 2018-07-31 2019-07-22 Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases

Publications (1)

Publication Number Publication Date
MX2020009757A true MX2020009757A (es) 2020-10-08

Family

ID=69232313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009757A MX2020009757A (es) 2018-07-31 2019-07-22 Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades.

Country Status (14)

Country Link
US (1) US11478469B2 (es)
EP (1) EP3672594B1 (es)
JP (1) JP7058345B2 (es)
KR (1) KR20210003731A (es)
CN (1) CN110772639B (es)
AU (1) AU2019314624B2 (es)
BR (1) BR112020018978A2 (es)
CA (1) CA3094449C (es)
EA (1) EA202091964A1 (es)
GE (1) GEP20237458B (es)
MX (1) MX2020009757A (es)
TW (1) TWI752335B (es)
UA (1) UA126098C2 (es)
WO (1) WO2020024820A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
WO2020024834A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
JP2021516262A (ja) 2018-07-31 2021-07-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド リツキシマブ及び／若しくはベンダムスチンと組み合わされたＢｃｌ−２阻害剤又はＣＨＯＰと組み合わされたＢｃｌ−２阻害剤の相乗的な抗腫瘍効果
EA202091964A1 (ru) 2018-07-31 2021-05-13 Эсентейдж Фарма (Сучжоу) Ко., Лтд. КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
AU2020323033A1 (en) * 2019-07-26 2021-04-22 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
TWI772992B (zh) * 2019-12-03 2022-08-01 大陸商蘇州亞盛藥業有限公司 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
US20220323465A1 (en) * 2019-12-04 2022-10-13 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
CN113337602A (zh) * 2020-03-02 2021-09-03 苏州亚盛药业有限公司 Mdm2抑制剂的治疗方法和生物标志物
CN113354636B (zh) * 2020-03-06 2022-08-09 苏州亚盛药业有限公司 N-(苯基磺酰基)苯甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
CN113521064A (zh) * 2020-04-14 2021-10-22 苏州亚盛药业有限公司 Mdm2抑制剂的新用途
US20240016747A1 (en) * 2020-11-25 2024-01-18 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
CN114681458B (zh) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 治疗多发性硬化症的方法
WO2023011488A1 (zh) * 2021-08-02 2023-02-09 苏州亚盛药业有限公司 一种药物组合及其用途
WO2023039160A1 (en) * 2021-09-09 2023-03-16 Kartos Therapeutics Methods of treating a cancer overexpressing one or more bcl-2 family proteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
EP2106451A4 (en) 2006-12-04 2010-12-15 Abbott Lab ACCOMPANYING DIAGNOSTIC TESTS FOR CANCER TREATMENT
WO2009086416A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
PE20142316A1 (es) 2008-12-05 2015-02-04 Abbvie Inc DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES
CA2751293A1 (en) 2009-02-11 2010-08-19 Abbott Laboratories Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
PE20120345A1 (es) 2009-05-26 2012-05-17 Abbvie Bahamas Ltd Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
NZ608274A (en) 2010-10-29 2015-05-29 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
DK2642999T3 (en) 2010-11-23 2017-01-09 Abbvie Ireland Unlimited Co METHODS OF TREATMENT FOR USING selectivity-VE BCL-2 INHIBITORS
MX343014B (es) 2010-11-23 2016-10-20 Abbvie Inc Sales y formas cristalinas de un agente inductor de apoptosis.
WO2012103059A2 (en) 2011-01-25 2012-08-02 The Regents Of The University Of Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
CN105246882A (zh) 2013-01-16 2016-01-13 密执安大学评议会 BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法
ES2818110T3 (es) 2014-02-28 2021-04-09 Merck Sharp & Dohme Tratamiento del cáncer con una combinación que comprende dinaciclib
CN106794171B (zh) * 2014-04-17 2020-03-24 密歇根大学董事会 Mdm2抑制剂和使用其的治疗方法
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
CN105061315B (zh) 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
AU2016314082B2 (en) * 2015-08-28 2019-07-25 Novartis Ag Mdm2 inhibitors and combinations thereof
WO2018027097A1 (en) 2016-08-05 2018-02-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
WO2020024834A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
EA202091964A1 (ru) 2018-07-31 2021-05-13 Эсентейдж Фарма (Сучжоу) Ко., Лтд. КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
JP2021516262A (ja) 2018-07-31 2021-07-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド リツキシマブ及び／若しくはベンダムスチンと組み合わされたＢｃｌ−２阻害剤又はＣＨＯＰと組み合わされたＢｃｌ−２阻害剤の相乗的な抗腫瘍効果
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
WO2020103921A1 (en) 2018-11-23 2020-05-28 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and use thereof

Also Published As

Publication number Publication date
AU2019314624B2 (en) 2022-03-03
US11478469B2 (en) 2022-10-25
WO2020024820A1 (en) 2020-02-06
JP7058345B2 (ja) 2022-04-21
EA202091964A1 (ru) 2021-05-13
CN110772639B (zh) 2021-04-13
EP3672594B1 (en) 2021-09-29
KR20210003731A (ko) 2021-01-12
TWI752335B (zh) 2022-01-11
TW202019407A (zh) 2020-06-01
EP3672594A1 (en) 2020-07-01
CA3094449A1 (en) 2020-02-06
GEP20237458B (en) 2023-01-10
JP2021525224A (ja) 2021-09-24
CA3094449C (en) 2023-02-28
CN110772639A (zh) 2020-02-11
US20220031694A1 (en) 2022-02-03
AU2019314624A1 (en) 2020-10-01
BR112020018978A2 (pt) 2021-03-02
UA126098C2 (uk) 2022-08-10
EP3672594A4 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
MX2020009757A (es) Producto combinado de inhibidor de bcl-2 e inhibidor de mdm2 y uso de este en la prevencion y/o tratamiento de enfermedades.
MX2020009758A (es) Producto combinado de inhibidor de bcl-2 o inhibidor dual de bcl-2/bcl-xl e inhibidor de btk y uso de este en la prevencion y/o tratamiento de enfermedades.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CO2020009625A2 (es) Inhibidor de fap
ECSP19042682A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
MX2022008868A (es) Tratamiento del cancer con tg02.
ZA201808537B (en) Combination therapies
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
CL2004000836A1 (es) Combinacion antineoplasica sinergica que comprende una combinacion de interferon alfa y cci-779; uso y producto que los contiene.
DOP2021000111A (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
MX2020009759A (es) Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
RS63401B1 (sr) Derivati 2,4-diaminohinazolina i njihova upotreba u lečenju virusnih infekcija, kancera ili alergija
TWD204810S (zh) 耳飾之部分
ECSP23019525A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
GEP20217301B (en) Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof
CU20190019A7 (es) Combinaciones que incluyen abx196 útiles en el tratamiento del cáncer
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CL2018001731A1 (es) Terapia de combinación.
BR112022004225A2 (pt) Uso de um inibidor de mdm2 para o tratamento de mielofibrose
CO2017006842A1 (es) Equipo biomedico electromagnetico